MGH Team Develops DNA-Based Assay for Single Cell Proteomics; NanoString Secures Option to IP | GenomeWeb

Researchers at Massachusetts General Hospital have developed a proteomic assay using DNA-barcoded antibodies that can simultaneously measure in the range of 100 proteins at single-cell sensitivity.

Detailed in a study published this week in Science Translational Medicine, the method uses NanoString Technologies' nCounter Analysis System as its readout platform. NanoString has an exclusive option from MGH to license the underlying IP.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.